Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

HP Additive Manufacturing: how hybrid design and 3D printing accelerate drone development, cut tooling costs, and strengthen supply chains.

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer made ...

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

Patients in a phase 2b trial kept losing weight after switching to monthly dosing of Pfizer’s GLP-1 receptor agonist, providing early validation of the drugmaker’s $10 billion bet on Metsera. The ...

CHONGQING, CHINA - JANUARY 29: In this photo illustration, a smartphone displays the logo of Pfizer Inc. (NYSE: PFE), an American multinational pharmaceutical company engaged in the development, ...

Pfizer (PFE) shares fell in the premarket on Tuesday after the company reaffirmed its full-year outlook, indicating a revenue contraction for 2026 amid a nearly $1.5B impact attributed to some of its ...

That's the good news. The bad news is that while Pfizer "beat" on both sales and adjusted earnings, its earnings as calculated according to generally accepted accounting principles (GAAP) showed a ...